Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
2,867 total articles
PepsiCo's pricing power, durable cash flow and an improving cost/mix backdrop support a tactical upgrade to long. The stock trades near $160 with a 3.5% yield, EV/EBITDA of 15.5 and FCF of $7.7B — valuations that leave room for upside as operating momentum normalizes. Trade plan provided for a mid-term swing (45 trading days).
LifeMD is cheaply priced for a telehealth platform that now offers GLP-1s (Wegovy/Ozempic) at competitive cash-pay rates, has positive free cash flow, and an enterprise value under $170M. With current technical momentum, a rising short interest profile, and clear distribution catalysts, a disciplined long with a $3.25 stop and $7.50 target offers a…
Hudson Technologies looks like an asymmetric opportunity: industrial cash-flow business, recent tuck-ins that expand recovered refrigerant supply, and valuation metrics (EV/EBITDA ~4.85, P/FCF ~5.58) that price in weakness. Technicals are oversold, creating a measured swing trade with a clear stop and a realistic target near prior highs.
Upstart is trading near its 52-week low despite improving technicals, a low RSI, and the prospect that a bank charter or similar deposit access could materially cut funding costs and lift margins. With a $2.67B market cap, negative free cash flow, and ongoing legal noise, this is a high-risk, high-reward swing trade: entry $27.00, stop $24.00, targ…
TJX's off-price model has continued to prove defensive and profitable: strong margins, high ROE, low leverage, and $4.4B of free cash flow underpin a mid-term long trade. Technicals show a neutral base near the 20-day moving average; I'll take a long swing with a defined entry at $157.50, a $170 target, and a $150 stop over ~45 trading days.
Oracle rallied after a clean Q3 beat and raised guidance, driven by 44% cloud growth, 84% infrastructure growth and a $553 billion backlog. The market is worried about heavy CapEx and negative free cash flow, but the worst of the spending fear may already be priced in. We outline a mid-term swing trade with explicit entry, stop and target while fla…
Kratos (KTOS) is a high-growth, government-facing unmanned systems and mission solutions company with recent contract wins, an expanded balance sheet via a $1.17B equity raise, and a pipeline into large programs like SHIELD. Valuation is rich but the company has low leverage, meaningful cash and a clear path to revenue growth. This trade idea lays …
Oracle's Q3 beats and a huge AI-driven backlog justify a tactical long. Strong cloud and infrastructure growth (OCI +84% in infra) and raised guidance to $90B create a path to meaningful multiple expansion, but heavy CapEx, negative free cash flow and large debt require a disciplined stop. We lay out an entry, target and stop for a mid-term (45 tra…
Oracle reported another quarter of robust cloud growth and a jaw-dropping $553 billion in remaining performance obligations, keeping the core growth story intact. The market has punished the name for heavy AI infrastructure spending and short-term cash-flow stress. This trade idea buys the dislocation: enter near $164.00, stop at $142.00, target $2…
Novo Nordisk traded near the low end of its range after a difficult 2025. The recent Hims & Hers agreement and resolution of litigation removes an uncertainty and creates a modest new distribution channel for Wegovy/Ozempic. At a market cap of roughly $172.4B and a P/E near 11, the stock offers asymmetric upside over the next 45 trading days if mom…
Kinsale's specialty underwriting economics and cash generation justify a buy here. The stock trades at a reasonable P/E with strong ROE and sizeable free cash flow, presenting a favorable risk/reward for a mid-term swing trade.
Royal Caribbean Group (RCL) is trading below momentum averages after a recent oil-driven selloff in travel names. With fuel tailwinds, record 2025 results, a 50% dividend increase and a sub-$100B enterprise value, the risk/reward favors a long trade targeting the consensus outlook near $350 over the next 6 months while using a clear stop to limit d…
Intuitive Surgical remains the leader in robotic-assisted surgery with strong recurring revenue from instruments and a growing installed base. Fundamental strength and long-term opportunity are intact, but a rich valuation (P/E ~61, market cap ~$172B) and rising competition argue for a Hold. For traders, consider a disciplined buy-on-weakness plan …
Nu Holdings ($NU) recently pulled back after a strong 2025 showing. With 45% revenue growth, reported customer counts above 100M, and a market cap near $70.2B, the company sits at an attractive risk/reward if credit performance and U.S. expansion clarity hold. This trade idea lays out a mid-term long with clear entry, target and stop.
Taiwan Semiconductor Manufacturing (TSM) dipped from recent highs as momentum cooled and short-volume ticked up. Fundamentals tied to the AI data-center buildout remain intact: TSMC controls the advanced foundry moat, reported strong 2025 revenue and EPS growth, and stands to benefit from hyperscaler capex. This trade plan buys the dip with a mid-t…
Micron has taken center stage in the AI memory race. With recent partnership news, analyst upgrades, and management signaling a robust Q2 ($18.7B revenue, $8.42 EPS), the stock looks set for another leg up into earnings. This is a momentum-driven, event-sensitive trade: enter $410.85, stop $385, target $520 with a short-term horizon (10 trading day…
United Natural Foods (UNFI) is cheap on multiple cash-flow metrics and is starting to show the early signs of margin recovery that the market may be underpricing. With free cash flow of $344M, EV/EBITDA ~10.6 and improving adjusted EPS guidance, a disciplined mid-term long where you buy into momentum and protect capital with a decisive stop makes s…
Monolithic Power Systems (MPWR) posts impressive profitability and cash generation, but the shares trade at a premium (roughly 82x EPS, ~18.6x sales) with momentum faltering. For traders willing to accept higher risk, a mid-term short (45 trading days) targeting a meaningful mean reversion offers an asymmetric trade: the fundamentals cushion downsi…
QuantumScape's engineering story has improved: QSE-5 samples, strategic supplier deals, and an Eagle pilot line move the company from lab promises closer to manufacturing reality. The stock, trading at $7.03 with a $4.29B market cap, still needs commercial-scale manufacturing proof. This trade idea buys the improved narrative while protecting capit…
Automatic Data Processing (ADP) is a Dividend King trading near its 52-week low with a 2.9% yield, $4.6B in free cash flow and a P/E of ~20.7. Weak near-term labor data and AI worries have driven the price lower, creating a defined-risk long trade targeting a valuation re-rate and steady cash return drivers.
Constellation Brands (STZ) looks like an actionable long trade as the company navigates a transitional 2026. The shares have pulled back from last year’s highs, valuation metrics (EV/EBITDA ~10.9x, P/E ~23.5x) are not demanding given $1.76B in free cash flow and a $26.1B market cap, and Berkshire Hathaway's interest plus recent beats create a favor…
Pagaya Technologies combines AI-driven credit underwriting with an asset-light pivot that has materially improved cash generation. At roughly 4x price-to-free-cash-flow and a market cap under $1.0B, the stock looks like a GARP (growth at a reasonable price) candidate. This trade idea outlines an entry, stop, targets, catalysts and balanced risks fo…
Hims & Hers (HIMS) just turned a legal liability into leverage: the Novo Nordisk partnership announced in early March resolved a major lawsuit and restores GLP-1 access to HIMS' telehealth channel. The stock is trading near $26.62 after a big gap; fundamentals still show strong revenue traction ($619M quarterly) and management targets $2.8B for 202…
Inspire Medical (INSP) is a leader in implantable therapy for obstructive sleep apnea. After a bruising product rollout and legal headlines, the balance sheet and cash flow remain intact, valuation is accessible and technical indicators show oversold conditions. This trade idea buys a recovery driven by improved billing, provider training completio…
Dell just reported blockbuster AI server results and laid out aggressive AI revenue targets. The stock has momentum, solid free cash flow, and valuation that still looks reasonable relative to the growth profile. This trade plan targets participation in the AI-led re-rating with defined entry, stop, and target levels and a long-term horizon of 180 …
